Payment overview · 2025
General Payments
$1,523.01
63 reported records · 21 companies
Healthcare provider profile · identity verified
Kepeng Lu, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LAS VEGAS, NV · NPI 1861856601
Verified facts
What the public records show
CMS Open Payments records show Kepeng Lu, PA received $1,523.01 in general payments during 2025 across 63 reported records.
Gilead Sciences, Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Paxlovid, Prolia, Vemlidy.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Kerendia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vemlidy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $253.22 | 16.6% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $222.27 | 14.6% | 8 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $183.03 | 12.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.59 | 9.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.11 | 7.2% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $109.47 | 7.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.28 | 5.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $56.92 | 3.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.63 | 3.3% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $48.36 | 3.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.33 | 3.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $39.78 | 2.6% | 2 | 2025 |
| HARTMANN USA, INC. | Unresolved — no canonical attribution shown | $25.83 | 1.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.68 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.61 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.70 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.17 | 1.3% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $17.28 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.37 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.81 | 1.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.57 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,523.01 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $222.27 | 8 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $183.03 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $109.47 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $87.44 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.28 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $76.45 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.80 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $56.92 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.15 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $55.15 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $50.63 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $48.36 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.33 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.66 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $39.78 | 2 | 2025 |
Source payment records
|
|||||
| ZETUVIT PLUS 10X10 P10 Normalized: zetuvit plus 10x10 p10 |
Device | HARTMANN USA, INC. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 112 |
| Losartan Potassium | Losartan Potassium | 146 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 139 | 56 |
| Metformin Hcl | Metformin Hcl | 113 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 26 |
| Montelukast Sodium | Montelukast Sodium | 93 | 42 |
| Omeprazole | Omeprazole | 85 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 81 | 25 |
| Alendronate Sodium | Alendronate Sodium | 79 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 23 |
| Gabapentin | Gabapentin | 55 | 21 |
| Metformin Hcl Er | Metformin Hcl | 54 | 19 |
| Vascepa | Icosapent Ethyl | 49 | 14 |
| Simvastatin | Simvastatin | 45 | 15 |
| Farxiga | Dapagliflozin Propanediol | 43 | 13 |
| Finasteride | Finasteride | 39 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 17 |
| Lisinopril | Lisinopril | 36 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | 17 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Kerendia | Finerenone | 31 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Valsartan | Valsartan | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Prolia | Denosumab | 17 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 13 |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,523.01 · 63 records | Gilead Sciences, Inc. | AIRSUPRA, AREXVY, CAPLYTA, CRYSVITA, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GEMTESA, General - Pain Management, ImmunoCAP, JARDIANCE, Kerendia, LEQVIO, NEXLETOL, OTEZLA, Ozempic, PAXLOVID, PROLIA, REPATHA, Rybelsus, SHINGRIX, TZIELD, Tymlos, Vemlidy, ZETUVIT PLUS 10X10 P10, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error